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Background: Nowadays, dried blood spots (DBS) are primarily used to obtain diagnostic access to risk collectives
such as intravenous drug users, who are prone to infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and
human immunodeficiency virus (HIV). Before DBS analyses can be used in this diagnostic context, however, a
comprehensive evaluation of its performance characteristics must be conducted. To the best of our knowledge, the
current study presents for the first time such essential data for the Abbott ARCHITECT system, which is currently the
worldwide leading platform in this field of infection diagnostics.
Methods: The investigation comprised 1,762 paired serum/DBS samples and a total of 3,524 determinations with
the Abbott ARCHITECT HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24-antigen/anti-HIV 1/2 assays as well as
with the artus HBV LC PCR and VERSANT HCV RNA qualitative (TMA) tests.
Results: In the context of DBS testing, a specificity of 100% was recorded for the seven serological and molecular
biological assays. The analytical sensitivity of HBsAg, anti-HBc, anti-HBs, anti-HCV, HIV-1-p24-antigen/anti-HIV 1/2,
HBV DNA, and HCV RNA detections in DBS eluates was 98.6%, 97.1%, 97.5%, 97.8%, 100%, 93%, and 100%,
respectively.
Discussion/conclusions: The results obtained indicate that it is today possible to reliably detect HBsAg, anti-HBc,
anti-HBs, anti-HCV and HIV-1-p24 antigen/anti-HIV 1/2 with state-of-the-art analytical systems such as the Abbott
ARCHITECT in DBS eluates even when a comparatively high elution volume of 1,000 μl is used. They also provide
evidence for the inherent analytical limits of DBS testing, which primarily concern the anti-HBc/anti-HBs system for
individuals with HIV infections and nucleic acid tests with relatively low analytical sensitivity.
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Blood samples dried on filter paper (dried blood spots,
DBS) were first used in human medical diagnostics by
Guthrie and Susi as a simple test for detecting phenylke-
tonuria [1]. Taking capillary blood samples is much eas-
ier than a venipuncture and does not require prompt
removal of the cellular components. Furthermore, anti-
bodies, many medications and their metabolites as well
as nucleic acids remain stable for much longer periods
in DBS than in whole blood, plasma or serum. Thus, it
is not surprising that the application field of DBS testing
has steadily broadened in the last five decades [2].
Today, DBS analysis is predominantly used in the course
of the diagnostics and therapy monitoring of chronic
diseases, such as infections caused by hepatitis B virus
(HBV), hepatitis C virus (HCV) and human immunode-
ficiency virus (HIV) in those parts of the world in which
cost-intensive, on-site laboratory medical infrastructure
cannot be made available for economic reasons [3-6]. In
high income countries, the “filter card technique” is pri-
marily employed to facilitate diagnosis of viral infections
in populations who have only limited access to healthcare.
Intravenous drug users are a large fraction of these groups
of people. They currently represent the main driving force
in HCV epidemiology in industrialized countries and gen-
erally benefit from the use of DBS analysis with regard to
their diagnostic detection [2,7-13].
The use of DBS thus offers many advantages in the
pre-analytical phase. However, from a purely laboratory
medical perspective, it is to be viewed critically because
it not only requires a time-consuming, manual sample
preparation, but also functions only with haemolytic elu-
ates, which are considered to be a problematical test ma-
terial per se [14]. There exist neither generally accepted
protocols for drying and elution of DBS [2,4,15], nor is it
known whether commercially available procedures for
serological or molecular HBV, HCV and HIV tests react
more or less similarly to the selected DBS elution condi-
tions. Consequently, comprehensive evaluations have to
be performed during the preliminary phases of any study
that desires to use the DBS technique [2].
To the best of our knowledge, the following study for
the first time presents data regarding the analytical per-
formance characteristics of testing HBsAg, anti-HBc,
anti-HBs, anti-HCV and HIV-1-p24-antigen/anti-HIV 1/
2 in DBS eluates with the Abbott ARCHITECT system,
i.e. the currently most frequently used platform world-
wide in this field of serological diagnostics (Abbott Diag-
nostics, personal communication). For the detection of
HBV DNA and HCV RNA from serum and DBS eluates,
a real-time PCR or an isothermal amplification tech-
nique were applied. Since the DBS testing is to be sub-
sequently employed in a multicentric, cross-sectional
study entitled “Drugs and Chronic Infectious Diseases”,for which a relatively high sample throughput in a com-
paratively short time is expected, the whole analytical
evaluation had to be based on elution conditions suitable
for routine use and was not designed for their optimisa-
tion for every individual parameter.
Results
The analytical tests comprised 1,762 paired serum/DBS
samples. They originated from 726 patients and formed
the basis for a total of 3,524 determinations. The results
of the comparative serum/DBS eluate investigations are
summarised in Table 1.
HBV detections
A total of 299 serum/DBS samples were tested for
HBsAg. One hundred fifty-nine sera were HBsAg nega-
tive and 140 HBsAg positive. In 45 paired analyses - for
each of which titrated HBsAg concentrations were avai-
lable - averages of 1,321 IU/ml (serum) and 83 IU/ml
(DBS eluates) were recorded (Figure 1). Overall, two dis-
crepant HBsAg results were found. The corresponding
test materials were obtained from two patients with
chronic HBV infections under antiviral treatment; one
of whom was anti-HIV positive. The HBsAg concen-
trations in the two sera were 749 IU/ml and 6 IU/ml.
Thus, a specificity of 100% and a sensitivity of 98.6%
were calculated for the HBsAg determination from
DBS.
The anti-HBc test was evaluated for a total of 305
paired serum/DBS samples. Overall, 101 of these speci-
mens exhibited no anti-HBc in the serum or in the
whole-blood eluates. Twenty-eight patients with positive
anti-HBc in serum were not detected by the DBS testing.
Twenty-two of these people had suffered from a HBV
infection; six exhibited the serological finding “anti-HBc
alone”. Twenty-two of the 28 affected individuals were
infected with HIV. Of the 22 resolved HBV infections
that were not detected in the DSB analysis, 20 were
assessed as “anti-HBs positive alone” and thus were fal-
sely classified as “condition after vaccination”. On the
basis of all 305 paired anti-HBc determinations, a speci-
ficity of 100% and a sensitivity of 86.3% resulted for the
testing of the whole blood eluates. In contrast, if subjects
with HIV infections had been excluded, a sensitivity of
97.1% was determined.
The analysis of the anti-HBs determinations comprised
310 serum/DBS samples. For specimens reactive in both
test materials, 107 titrated anti-HBs concentrations were
available; on average they exhibited concentrations of
280 IU/l (serum) and 23 IU/l (DBS eluate) (Figure 1). In
total, nine discrepant results occurred. In all these cases,
serum anti-HBs concentrations of 11 to 26 IU/l, which
were too low to be detected after elution of the dried
whole blood, were found. The uncorrected specificity
Table 1 Analytical specificity and sensitivity of the DBS eluate testing for markers of HBV, HCV and HIV infections
compared to serum analyses
Parameters Serum DBS eluates Specificity (%)/ 95% CIa) Sensitivity (%)/ 95% CIa)
n. d. (N) pos. (N) n. d. (N) pos. (N)
HBV
HBsAg 159 140 161 138 100/97.7 – 100 98.6/94.9 – 99.8
Anti-HBc 101 204 129b) 176b) 100/97.2 – 100 86.3/83.0 – 91.8b)
107c) 198c) 97.1/93.9 – 99.0c)
Anti-HBs 153 157 162b) 148b) 100/97.6 – 100 94.3/90.0 – 97.5b)
157c) 153c) 97.5/93.8 – 99.3c)
HBV DNA 50 100 107 93 100/96.1 – 100 93.0/92.9 – 93.1
HCV
Anti-HCV 160 179 164 175 100/97.7 – 100 97.8/96.0 – 100
HCV RNA 50 100 50 100 100/96.1 – 100 100/98.0 – 100
HIV
HIV-1-p24/anti-HIV 1/2 97 112 97 112 100/96.3 – 100 100/96.8 – 100
The results of the serum analyses served as reference for the calculation of the analytical performance characteristics of the DBS testing. — n. d.: not detectable;
pos.: positive.
a) 95% confidence interval calculated according to Clopper and Paerson [50]. b) Calculated with inclusion of the results obtained from HIV infected individuals.
c) Calculated without the results recorded from HIV infected individuals.
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amounted to values of 100% and 94.3%, respectively. If
the samples that originated from HIV positive persons
were not included, the sensitivity rose to 97.5%.
DBS testing of 50 individuals negative for HBV DNA
did not reveal any non-specificity. The determination
of the sensitivity of the qualitative HBV DNA testing
from whole blood eluates was performed on 100 speci-
mens (mean DNA concentration: 1,573,898 IU/ml,
range: < 357 - > 17,860,000 IU/ml) and yielded a value
of 93.0%. Thus, seven samples with low serum HBV
DNA concentrations between 409 and 3,643 IU/ml









Figure 1 Distribution of the HBsAg (A) and anti-HBs concentrations (B
values were available. The “whiskers” on the box plots each represent 1.5
thresholds appear separately and are thus tagged as outliers.HCV detections
Anti-HCV antibodies were determined in 339 whole
blood samples as well as in the sera obtained from them.
The measurements of the DBS eluates achieved a speci-
ficity of 100% and a sensitivity of 97.8%. The four false
negative anti-HCV results all involved patients whose
sera showed weak anti-HCV reactivities in immunoassay
(S/Co 1.2 – 2.65). Only in one case could the positive re-
action for anti-HCV also be confirmed in immunoblot.
As, in addition, no HCV RNA was detectable for any of
those individuals affected (in some cases repeatedly), it
is very probable that HCV infections, from which the









) in 45 or 107 serum/DBS pairs, respectively, for which titrated
times the interquartile range. Values that lie above or below these
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low antibody concentration.
DBS testing of 50 HCV RNA-negative individuals
did not result in any non-specificity. Of 100 sera which
had proven to be HCV RNA positive (mean HCV RNA
concentration: 1,415,944 IU/ml, range: 2,479 - >7,692,000
IU/ml), corresponding whole blood aliquots were avail-
able. The comparative investigation resulted in an analyt-
ical sensitivity of 100% for HCV RNA determinations
from DBS eluates.
HIV detections
The analysis of 209 serum/DBS eluate pairs for HIV-1-
p24-antigen/anti-HIV 1/2 provided consistently corre-
sponding results and thus a specificity and sensitivity of
100% for the DBS testing in each case.
Discussion
To the best of our knowledge, the current study for
the first time presents data on the analytical perform-
ance characteristics of testing HBsAg, anti-HBc, anti-
HBs, anti-HCV and HIV-1-p24-antigen/anti-HIV 1/2 in
DBS eluates with the Abbott ARCHITECT system, i.e.
the currently most frequently used platform worldwide
in this field of serological diagnostics (Abbott Diag-
nostics, personal communication). Our whole analytical
evaluation had to be based on elution conditions suitable
for routine use and was not designed to achieve an opti-
misation for every individual parameter. Consequently,
the DBS for the five antigen and antibody tests were
eluted with a total of 1,000 μl of a PBS-based buffer with
Tween 20 overnight at room temperature [16]. The
whole blood eluates for the performance of HBV DNA
and HCV RNA tests were prepared under identical con-
ditions in a second operation. The analytical tests com-
prised 1,762 paired serum/whole blood samples. They
originated from 726 patients and were the basis for a
total of 3,524 determinations.
There was no analytical non-specificity in serological
and molecular biological DBS testing.
The detection of HBsAg positive materials from whole
blood eluates succeeded with a sensitivity of 98.6% to a
similarly high degree as in previous studies, which had
in part used a much smaller elution volume of, for ex-
ample, 100 μl [17], 250 or 600 μl [18], or 500 μl [19]. In
the two non-detected DBS samples, there were HBsAg
concentrations of 749 IU/ml and 6 IU/ml. Such a low
antigenaemia would probably hardly ever occur in cur-
rently injecting drug users chronically infected with
HBV because the majority of those people does not re-
ceive antiviral treatment [20].
Whether the serum anti-HBc/anti-HBs system for the
differentiation of previous HBV infections, on the one
hand, and antibody titres as a result of vaccination, onthe other hand, is generally also appropriate in DBS elu-
ates has been very rarely investigated to date. Komas
and co-workers [19] determined an analytical specificity
and sensitivity of 100% for both tests in 15 and 10 corre-
sponding serum/DBS pairs, respectively. In contrast,
Tappin et al. [21] were only able to detect anti-HBc
antibodies in DBS eluates from 7-day old neonates
in 44 of 56 cases (sensitivity: 79%) with a modified
hemagglutination assay. Another investigation indicated
in an exemplary manner that the anti-HBc/anti-HBs sys-
tem definitely reacts critically to dilution [18]. Whereas
the anti-HBc antibodies in the whole blood eluates were
detected independently of the elution volumes (150 or
600 μl) in twelve patients chronically infected with HBV,
twelve resolved HBV infections could only then be cor-
rectly recorded if the quantity of buffer used to eluate
the DBS did not exceed 250 μl. The observations we
made on the Abbott ARCHITECT system with an elu-
tion volume of 1.000 μl confirm these results communi-
cated by Villa et al. [18] in as much as the anti-HBc/
anti-HBs system completely failed when it was used on
individuals infected with HIV. In addition, our results
prove that immunocompetent persons can also be tested
false negative for anti-HBc and anti-HBs in rare cases.
This applies particularly to subjects with very low anti-
HBc and anti-HBs concentrations in serum.
As a result of its comparatively high detection limit of
100 IU HBV DNA/ml, the artus HBV LC PCR Kit [22]
used for DBS testing in this study turned out to be just
as reliable as the Cobas Amplicor HBV Monitor Test
[23,24] or an in-house rt-PCR [25] and was therefore
not superior to older procedures with conventional end-
point detection [26]. For the projected study “Drugs and
Chronic Infectious Diseases”, in the course of which
DBS testing is to occur, this means that the presumably
small number of study participants who had received
antiviral treatment could be overlooked, just as could
those with a chronic HBV infection and a generally low
viremia on the basis of the serological finding “anti-HBc
alone” [27].
The detection of anti-HCV antibodies with the ARCHI-
TECT system was a predominantly smooth process for
whole blood eluates. The sensitivity of 97.8% determined
in the investigation of 179 serum/DBS pairs corresponded
to the results obtained in existing studies [16,28-31],
which however had worked with an elution volume that
was lower by a factor of 5 to 10. In addition, the pro-
tocols for anti-HCV detection had been appropriately
optimised, in contrast to our analyses, by, e. g., stipu-
lating their own cut-off points [16,29,31] or by increa-
sing the sample volumes used from 20 μl to 100 μl
[31]. The fact that in our study four patients with
presumably already long since resolved HCV infec-
tions were not recognised clearly illustrates the limits
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fully considered when employing this approach in col-
lectives such as intravenous drug users. In this context,
due to the high anti-HCV prevalence, a substantial abso-
lute number of people with resolved HCV infections and
consequently low anti-HCV concentrations are to be ex-
pected [32]; they could, at least partially, evade detection
by DBS testing due to the dilution used.
The excellent analytical sensitivity of the HCV RNA
test with TMA (circa 5 IU HCV RNA/ml) [33,34] is also
reflected in the results of our DBS analysis and allows
this approach to appear more promising than the use of
an in-house real-time PCR procedure [35] or a multiplex
methodology with detection of the amplification prod-
ucts by means of SYBR Green [36]. However, by way of
qualification, it must be said that the mean serum HCV
RNA concentration in the 100 samples that we exam-
ined with approximately 1.4 million IU/ml was relatively
high. Since a dilution factor of 16.5 – 18.2 between HCV
RNA positive sera and whole blood eluates obtained
with a volume of 500 μl was calculated for determina-
tions with TMA in a previous investigation [37], an ap-
proximate TMA detection limit of 165 – 182 IU HCV
RNA/ml may be assumed under the conditions that we
used (1,000 μl elution volume) for the DBS testing.
Therefore, the two samples with HCV RNA concentra-
tions of 178 and 331 IU/ml, which Tuailon et al. [31]
classified as false negative, could possibly also have es-
caped from our TMA analysis. This means that a differ-
ence in sensitivity of 97% [31] and the value of 100%
which we determined could be simply random.
HIV-1-p24-antigen/anti-HIV 1/2 was ultimately detec-
ted with the Abbott ARCHITECT system in the eluted
whole blood of all 112 infected persons. Thus, the rather
unfavourable routine elution conditions used in this in-
vestigation proved to be in no way disadvantageous. The
determined ideal analytic specificity and sensitivity of
100% each were not only equal or superior to the per-
formance characteristics established with other immuno-
assays which have been specifically adapted to DBS testing
[38,39] or a stepwise procedure with the combined use
of several anti-HIV tests [40]. They, indeed, also excee-
ded the performance record of an assay that had been
specially developed and optimised for the detection of
anti-HIV antibodies in DBS eluates (Q-Prevent HIV 1 +
2 DBS kit) [41].
Conclusions
The performed study shows that it is nowadays possible
to reliably detect HBsAg, anti-HCV and HIV-1-p24-anti-
gen/anti HIV 1/2 with state-of-the-art analytical systems
such as the Abbott ARCHITECT in DBS eluates even
when a comparatively high elution volume of 1,000 μl is
used and modifications of the protocols established forserum or plasma investigations are largely dispensed
with. However, the communicated results also confirm
the inherent analytical limits of DBS testing. It fails, for
example, completely in the anti-HBc/anti-HBs system
for those individuals infected with HIV due to the low
antibody concentrations; it proved to be definitely prob-
lematical in the recognition of HCV infections which
had long since been resolved; and it required molecular
biological procedures with optimal analytical sensitivity
with regard to HBV DNA and HCV RNA tests. Due to
our findings, the projected screening algorithm for the
upcoming cross-sectional study “Drugs and Chronic In-
fectious Diseases” was modified. Individuals infected
with HIV will be always tested for the presence of HBV
DNA. Participants whose DBS eluates are positive for
anti-HBc or anti-HBs should be subjected to a venipunc-
ture during a second consultation in order to definitely
clarify their anti-HBc/antiHBs status and, finally, all DBS
eluates will be screened for HCV RNA regardless of the
results of anti-HCV testing.
Methods
Paired serum/DBS samples obtained from 726 patients
were included into this study. Upon admission to our
hospital, patients provided written consent to all neces-
sary biochemical, bacteriological, and virological investi-
gations. All samples used throughout the study were
sent to our laboratory in the process of routine clinical
diagnostics. Thus, none of the specimens was collected
specifically for the purpose of the study, not a single
additional venipuncture was performed and none of the
materials was tested for any parameter other than those
required by the physicians in the course of the normal
diagnostic work-up. Given these circumstances, approval
by an ethics committee seemed to be dispensable.
To prepare the DBS, 100 μl of whole blood were ini-
tially applied to a Whatman/Schleicher & Schüll (Dassel,
Germany) #903 filter paper and subsequently dried over-
night [4,6]. For the five antigen and antibody tests the
DBS were eluted with 1,000 μl of a buffer (PBS/0.05%
Tween 20/0.08% sodium azide) overnight at room tem-
perature on a shaker [16]. This was followed by centrifu-
gation of the eluates for two minutes at 10,000 rpm. The
whole blood eluates for the performance of HBV DNA
and HCV RNA tests were obtained under identical con-
ditions in a second operation.
The DBS eluates as well as the corresponding sera
were tested for HBsAg [42], anti-HBc [43], anti-HBs
[44], anti-HCV [45] as well as for the simultaneous pres-
ence of HIV-1-p24-antigen and antibodies against HIV
1/2 (HIV Ag/Ab Combo) [46] using the ARCHITECT
system (Abbott Diagnostics, Delkenheim, Germany).
The measurements generally adhered to the manufac-
turer’s recommendations, but had to be modified for
Figure 2 HBsAg and anti-HBs testing in DBS eluates. Separation of positive from negative materials after changing the cut-off values to
0.15 IU/ml (HBsAg) (A) and 1.5 IU/l (anti-HBs) (B), respectively.
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unavoidable haemolysis, it was necessary to increase the
cut-off value of the HBsAg determination from ≥ 0.05
to ≥ 0.15 IU/ml. On the other hand, to compensate for
the effect of dilution the threshold of a positive reac-
tion to anti-HBs was lowered from ≥ 10.0 to ≥ 1.5 IU/l.
These changes in the cut-off values neither impaired the
discrimination of HBsAg-positive and –negative samples
nor affected the assignment of anti-HBs-reactive and –
non-reactive materials. However, as shown in Figure 2,
the interval separating positives and negatives was con-
sequently lowered to 0.12 - 0.19 IU/ml (HBsAg) and
1.45 – 2.07 IU/l (anti-HBs). Abbott HBsAg neutralisation
tests as well as anti-HCV and anti-HIV immunoblots
were not used in the context of DBS testing because
the tentative protocol of the projected study “Drugs and
Chronic Infectious Disease” specified that every reactive
HBsAg and anti-HCV finding in the immunoassay is to be
verified by a nucleic acid test and that positive anti-HIV
results established in DBS eluates are to be confirmed by
two independent analyses from serum.
Serum and DBS eluates were subjected to nucleic acid
extraction by the MagNa Pure 96 system using Viral NA
Universal kit (Roche Diagnostics, Mannheim, Germany).
The artus HBV LC PCR (Qiagen, Hilden, Germany) [22]
and the VERSANT HCV RNA qualitative (TMA) systems
(Siemens Healthcare Diagnostics, Eschborn, Germany)
[33] were used for the qualitative determination of HBV
DNA and HCV RNA; their detection limits are 100 IU/ml
and 5 IU/ml, respectively. The b-DNA technology was
employed for quantification in serum (VERSANT HBV
bDNA 3.0 assay and VERSANT HCV RNA 3.0 Assay,
Siemens Healthcare Diagnostics, Eschborn, Germany)
[47-49].
The data was analysed with Predictive Analytics Soft-
ware (PASW), Version 18 (SPSS, Chicago, IL, USA).
Confidence intervals were calculated according to Clopperand Pearson [50] employing the R Project for Statistical
Computing (available at: http://R-project.org. Last acces-
sed: 10 March, 2013).
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